GLP-1 (glucagon-like peptide-1) Agonists Step Therapy Program Summary

This program applies to Medicaid. It is implemented with auto-grandfathering.

Step Therapy only applies to the MN Medicaid Preferred Drug List (PDL) preferred drugs: Byetta, Bydureon pens, and Victoza.

The BCBS MN Step Therapy Supplement also applies to this program for Medicaid.

Program specific denial language for prerequisite step therapy component does not apply. Instead, supplemental program denial language will apply.

<table>
<thead>
<tr>
<th>GLP-1 Agonist</th>
<th>Indication</th>
<th>Important limitations for use</th>
<th>Dosage and Administration</th>
</tr>
</thead>
</table>
| Adlyxin (lixisenatide) | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. | • Adlyxin has not been studied in patients with chronic pancreatitis or a history of unexplained pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.  
• Adlyxin is not a substitute for insulin. Adlyxin is not indicated for use in patients with type 1 diabetes mellitus or for treatment of diabetic ketoacidosis.  
• The concurrent use of Adlyxin with short acting insulin has not been studied and is not recommended.  
• Adlyxin has not been studied in patients with gastroparesis and is not recommended in patients with gastroparesis. | • Starting dose of 10 mcg subcutaneously once daily for 14 days.  
• Increase the dose to the maintenance dose of 20 mcg once daily starting on Day 15. |

Available as:  
Starter Pack: For treatment initiation, 1 prefilled green pen of 10 mcg and 1 prefilled burgundy pen of 20 mcg  
Maintenance Pack: 2 prefilled burgundy pens of 20 mcg
<table>
<thead>
<tr>
<th>GLP-1 Agonist</th>
<th>Indication</th>
<th>Important limitations for use</th>
<th>Dosage and Administration</th>
</tr>
</thead>
</table>
| **Bydureon** (exenatide extended-release) Injection | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. | • Not recommended as first-line therapy for patients inadequately controlled on diet and exercise.  
• Not a substitute for insulin. Should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.  
• Concurrent use with insulin has not been studied and cannot be recommended.  
• Bydureon has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis. | • Inject subcutaneously 2 mg once weekly at any time of day, with or without meals. The day of weekly administration can be changed if necessary as long as the last dose was administered 3 or more days before.  
• Injection should be in the abdomen, thigh or upper arm. |
| **Available as:** 2 mg vial in single-dose tray with syringe of diluent and needle; 4 trays per carton  
2 mg single-dose pen supplied in cartons with 4 pens and needle | | | |
| **Bydureon BCise** (exenatide extended release) Injection | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. | • Not recommended as first-line therapy for patients inadequately controlled on diet and exercise.  
• Should not be used to treat type 1 diabetes or diabetic ketoacidosis.  
• Use with insulin has not been studied and is not recommended.  
• Bydureon BCise is an extended-release formulation of exenatide. Do not coadminister with other exenatide containing products.  
• Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis. | • Administer 2 mg by subcutaneous injection once every seven days (weekly), at any time of day and with or without meals.  
• Administer immediately after the dose is prepared. |
<p>| <strong>Available as:</strong> 2 mg single-dose auto-injector supplied in cartons with 4 auto-injectors | | | |</p>
<table>
<thead>
<tr>
<th>GLP-1 Agonist</th>
<th>Indication</th>
<th>Important limitations for use</th>
<th>Dosage and Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Byetta</strong> (exenatide)</td>
<td>Injection Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</td>
<td>• Not a substitute for insulin. Should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.</td>
<td>• Inject subcutaneously within 60 minutes prior to morning and evening meals (or before the 2 main meals of the day, approximately 6 hours or more apart).</td>
</tr>
<tr>
<td><strong>Available as:</strong></td>
<td>250 mcg/mL in: 5 mcg per dose, 60 doses, 1.2 mL prefilled pen</td>
<td>• Concurrent use with insulin has not been studied and cannot be recommended.</td>
<td>• Initiate at 5 mcg per dose twice daily; increase to 10 mcg twice daily after 1 month based on clinical response.</td>
</tr>
<tr>
<td></td>
<td>10 mcg per dose, 60 doses, 2.4 mL prefilled pen</td>
<td>• Byetta has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.</td>
<td></td>
</tr>
<tr>
<td><strong>Ozempic</strong> (semaglutide)</td>
<td>Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</td>
<td>• Ozempic is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of rodent C-cell tumor findings to humans.</td>
<td>• Administer once weekly at any time of day, with or without regard to meals.</td>
</tr>
<tr>
<td><strong>Available as:</strong></td>
<td>Single-patient-use-pen, in cartons of one 2 mg pen delivering doses 0.25-0.5 mg per injection; and in cartons of two 2 mg pens delivering 1 mg per injection</td>
<td>• Ozempic has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.</td>
<td>• Initiate at 0.25 mg subcutaneously once weekly. Dose can be increased to 0.5 mg once weekly after 4 weeks, and the increased to 1 mg once weekly after 4 weeks of 0.5 mg once weekly therapy.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis.</td>
<td>• Inject subcutaneously in the abdomen, thigh, or upper arm.</td>
</tr>
<tr>
<td>GLP-1 Agonist</td>
<td>Indication</td>
<td>Important limitations for use</td>
<td>Dosage and Administration</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Rybelsus® (semaglutide) tablet | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus | • Not recommended as first-line therapy for patients inadequately controlled on diet and exercise  
• Has not been studied in patients with a history of pancreatitis  
• Not indicated for use in patients with type 1 diabetes mellitus or treatment of diabetic ketoacidosis | • Take at least 30 minutes before the first food, beverage, or other oral medications of the day with no more than 4 ounces of plain water only  
• Start with 3 mg once daily for 30 days. After 30 days on the 3 mg dose, increase the dose to 7 mg once daily.  
• Dose may be increased to 14 mg once daily if additional glycemic control is needed after at least 30 days on the 7 mg dose |
<table>
<thead>
<tr>
<th>GLP-1 Agonist</th>
<th>Indication</th>
<th>Important limitations for use</th>
<th>Dosage and Administration</th>
</tr>
</thead>
</table>
| Tanzeum (albiglutide for injection, for subcutaneous (SC) use) | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. | • Tanzeum is not indicated in the treatment of patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis  
• Not recommended as first-line therapy for patients inadequately controlled on diet and exercise.  
• Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.  
• Has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis. Use is not recommended in patients with pre-existing severe gastrointestinal disease.  
• Has not been studied in combination with prandial insulin. | • Administer once weekly at any time of day, without regard to meals.  
• Initiate at 30 mg subcutaneously once weekly. Dose can be increased to 50 mg once weekly in patients requiring additional glycemic control.  
• Inject subcutaneously in the abdomen, thigh, or upper arm. |

Available as: single-dose pens for injection, in cartons of 4 syringes plus needles, in doses of 30 mg and 50 mg.
<table>
<thead>
<tr>
<th>GLP-1 Agonist</th>
<th>Indication</th>
<th>Important limitations for use</th>
<th>Dosage and Administration</th>
</tr>
</thead>
</table>
| **Trulicity**       | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. | • Not recommended as first-line therapy for patients inadequately controlled on diet and exercise  
• Has not been studied in patients with a history of pancreatitis. Consider another antidiabetic therapy in patients with a history of pancreatitis  
• Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis.  
• Not for patients with pre-existing severe gastrointestinal disease.  
• Has not been studied in combination with basal insulin | • Administer once weekly at any time of day  
• Inject subcutaneously in the abdomen, thigh, or upper arm  
• Initiate at 0.75 mg subcutaneously once weekly. Dose can be increased to 1.5 mg once weekly for additional glycemic control |
| (dulaglutide for SC injection) | Available as: Single dose pens and prefilled syringes |                                                                                               |                                                                                           |
| **Victoza**         | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. | • Victoza is not a substitute for insulin. Victoza should not be used in patients with type 1 diabetes mellitus or for the treatment of or diabetic ketoacidosis.  
• Concurrent use with prandial insulin has not been studied. | • Administer once daily at any time of day.  
• The injection site and timing can be changed without dose adjustment.  
• Initiate at 0.6 mg per day for one week. This dose is intended to reduce GI symptoms during initial titration, and is not effective for glycemic control. After 1 week, increase the dose to 1.2 mg. If 1.2 mg dose does not result in acceptable glycemic control, dose can be increased to 1.8 mg.  
• When initiating, consider reducing the dose of concomitantly-administered insulin secretagogues to reduce the risk of hypoglycemia. |
| (liraglutide [rDNA origin] injection), solution for subcutaneous (SC) use | To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease |                                                                                               |                                                                                           |
| Available as: Solution for subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg (6 mg/mL, 3 mL) |                                                                                               |                                                                                               |                                                                                           |
CLINICAL RATIONALE
Both the American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) recommend metformin as the optimal non-insulin first-line drug in type II diabetes mellitus.7,8 Two-drug combinations should be used if metformin fails to achieve A1c target after approximately 3 months.7,8 The choice of the second agent (sulfonylurea, thiazolidinedione, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 inhibitor, basal insulin, glucagon-like peptide 1 agonist) is based upon patient and drug characteristics, with the goal of improving glycemic control while minimizing side effects.7,8

REFERENCES
GLP-1 (glucagon-like peptide-1) Agonists Step Therapy

OBJECTIVE
The intent of the GLP-1 (glucagon-like peptide-1) Agonists Step Therapy (ST) program is to promote appropriate selection of patients based on product labeling, and/or clinical guidelines, and/or clinical studies. Appropriate patients for GLP-1 agonist therapy are those who are concurrently receiving or have tried an agent containing metformin or sulfonylurea, insulin, or insulin/GLP-1. The step edit allows continuation of therapy when patients are currently receiving the requested agent. Patients without prerequisite agents in claims history or those who are unable to take a prerequisite agent due to documented intolerance, FDA labeled contraindication, or hypersensitivity will be reviewed when patient-specific documentation has been provided.

TARGET AGENTS
- Adlyxin™ (lixisenatide)
- Byetta® (exenatide)
- Bydureon™ (exenatide extended-release)
- Bydureon BCise™ (exenatide extended-release)
- Ozempic® (semaglutide)
- Rybelsus® (semaglutide)
- Tanzeum™ (albiglutide)
- Trulicity™ (dulaglutide)
- Victoza® (liraglutide)

PRIOR AUTHORIZATION CRITERIA FOR APPROVAL
Target Agents will be approved when ONE of the following is met:
1. The patient’s medication history includes one or more of the following antidiabetic agents (an agent containing metformin or sulfonylurea, insulin, or insulin/GLP-1) in the past 90 days
   OR
2. There is documentation that the patient is currently using the requested agent
   OR
3. The prescriber states the patient is using the requested agent AND is at risk if therapy is changed
   OR
4. The patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to at least one of the following agents: metformin, sulfonylurea, or insulin

Length of approval: 12 months

NOTE: If Quantity Limit program also applies, please refer to Quantity Limit documents.
Step Therapy Supplement Program Summary

This program applies to Medicaid.

Please note, this does not include or apply to quantity limit questions.

STEP THERAPY SUPPLEMENT OBJECTIVE
The intent of the Step Therapy Supplement is to provide additional questions, to ensure compliance to MN Statute 62Q.184. These questions will apply if the step therapy component within a Prior Authorization or Step Therapy program is not able to be approved.

CONDITIONS FOR APPROVAL
The requested agent will be approved when ONE of the following are met:

1. The patient is currently being treated with the requested agent as indicated by ALL of the following:
   a. A statement by the prescriber that the patient is currently taking the requested agent
   AND
   b. A statement by the prescriber that the patient is currently receiving a positive therapeutic outcome on requested agent
   AND
   c. The prescriber states that a change in therapy is expected to be ineffective or cause harm

OR

2. BOTH of the following
   a. The patient’s medication history includes the required prerequisite/preferred agent(s) or a drug in the same pharmacological class with the same mechanism of action as indicated by ONE of the following:
      i. Evidence of a paid claim(s) within the past 999 days
      OR
      ii. The prescriber has stated that the patient has tried the required prerequisite/preferred agent(s) in the past 999 days
   AND
   b. ONE of the following:
      i. The required prerequisite/preferred agent(s) was discontinued due to lack of effectiveness or an adverse event
      OR
      ii. The prescriber has submitted an evidence-based and peer-reviewed clinical practice guideline supporting the use of the requested agent over the prerequisite/preferred agent(s)

OR

3. The prescriber has provided documentation that the required prerequisite/preferred agent(s) cannot be used due to a documented medical condition or comorbid condition that is likely to cause an adverse reaction, decrease ability of the patient to achieve or maintain reasonable functional ability in performing daily activities or cause physical or mental harm

Length of Approval: As per program specific criteria